Catherine Sebban

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +10

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +6

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Marc André, T. Girinsky, Massimo Federico et al. · Journal of Clinical Oncology · 2017 · 532 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

Franck Morschhauser, John Radford, Achiel Van Hoof et al. · Journal of Clinical Oncology · 2008 · 460 citations

Medicine, Oncology, Pharmacotherapy +17

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Olivier Hermine, Eva Hoster, Jan Walewski et al. · The Lancet · 2016 · 401 citations

Medicine, Immunology, Oncology +17